---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-108572"
form_type: "8-K"
ticker: "APM"
cik: "0001734005"
company_name: "Aptorum Group Ltd"
filed_at: "2026-10-09T21:12:08+00:00"
generated_at: "2026-10-12T14:59:22.871005+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Niki BioSolutions signs ATM sales agreement with H.C. Wainwright for up to $1,396,000 of common stock

## Summary
- Sales Agreement dated October 9, 2026 lets Niki BioSolutions (NIKI) sell up to $1,396,000 of common stock through H.C. Wainwright as sales agent or principal.
- Wainwright earns a 3.0% placement fee on gross sales as agent; Brookline Capital Markets acts as qualified independent underwriter for no additional compensation.
- Director and largest shareholder Dr. Kira Sheinerman is a Wainwright managing director, creating a FINRA Rule 5121 conflict; Wainwright cannot sell to discretionary accounts without written approval.
- Offering falls under a Form S-3 shelf (File No. 333-298608) declared effective October 9, 2026; exhibits include the Sales Agreement (1.1) and Hunter Taubman Fischer & Li opinion (5.1).

## SEC filing metadata
- accession: 0001213900-26-108572
- form_type: 8-K
- ticker: APM
- cik: 0001734005
- company_name: Aptorum Group Ltd
- filed_at: 2026-10-09T21:12:08+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1734005/000121390026108572/0001213900-26-108572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1734005/000121390026108572/ea0308263-8k_nikibio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-108572
- JSON: https://secwatch.observer/filing/0001213900-26-108572.json
- Plain text: https://secwatch.observer/filing/0001213900-26-108572.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.